Next-generation ADCs: payload innovation
zanidatamab 新辅助 · No-chemo pCR 30%, HER2 down 56%
This is a breaking report from AACR, one of the world's largest cancer research conferences. The anti-HER2 bispecific antibody zanidatamab has been reported, based on results from the phase 2 NeoZanHER trial, to potentially be effective as neoadjuvant therapy for HER2-positive
Heat 7 · 7 likes · 0 replies · 0 reposts
Ankur Karmokar, Emanuele Loro, Al Hassan Kyakulaga, Desmond Lau, Nina Weisser, Genevieve Desjardins, Prajwal Raghunatha, Edwin Clark, Robin Humphreys, Kedar S. Vaidya
Read the abstract →Vicente Valero, Paula R. Pohlmann, Jason Mouabbi, Xuelin Huang, Wei Qiao, Heather R. Alonzo, Rashmi Krishna Murthy, Gaiane M. Rauch, Taiwo Adesoye, Cristina M. Checka, William F. Symmans, Dmitri Grachev, Flora Alajajyan, Adaeze Nwosu-Iheme, Amy Hassan, Miral Mahesh Patel, Sharon H. Giordano, Kelly Hunt, Debasish Tripathy, Funda Meric-Bernstam
Read the abstract →Vivek Subbiah, Vicky Makker, Do-Youn Oh, Elizabeth Gardener, Elaina Gartner, Funda Meric-Bernstam
Read the abstract →Source: cancer_navi · x.com